Increasing non-susceptibility to antibiotics within carried pneumococcal serotypes — Alaska, 2008–2015. Issue 27 (2nd June 2020)

• Record Type: Journal Article
• Authors: Plumb, Ian D.; Gounder, Prabhu P.; Bruden, Dana J.T.; Bulkow, Lisa R.; Rudolph, Karen M.; Singleton, Rosalyn J.; Hennessy, Thomas W.; Bruce, Michael G.
• Is Part Of: Vaccine. Volume 38:Issue 27(2020)
• Page Start: 4273
• Page End: 4280
• Publication Date: 2020-06-02
• Subjects: Streptococcus pneumoniae -- Pneumococcal -- Serotype -- Resistance -- Pneumococcal conjugate vaccine -- PCV13; Vaccines -- Periodicals; 615.372
• DOI: 10.1016/j.vaccine.2020.04.048
• Languages: English
• ISSNs: 0264-410X

Abstract

Abstract: Background: In Alaska, while introduction of 13-valent pneumococcal conjugate vaccine led to declines in invasive pneumococcal disease, carriage prevalence remained stable because of replacement with non-vaccine serotypes. We assessed antibiotic non-susceptibility of carried pneumococci during serotype redistribution, determined the contributions of within-serotype shifts, and assessed factors that could explain changes in non-susceptibility. Methods: Each year from 2008 to 2015, at multiple sites in Alaska, we collected nasopharyngeal swabs and completed surveys for a convenience sample of participants. Pneumococcal serotyping and antimicrobial susceptibility testing for penicillin and erythromycin were performed. We described changes in non-susceptibility of isolates from 2008–2011 to 2012–2015, and assessed the contributions of serotype redistribution and within-serotype changes in non-susceptibility by comparing observed data to modeled data removing either factor. We used weighted logistic regression to assess whether reported risk factors could explain changes over time in non-susceptibility within serotypes. Results: From 2008–2011 to 2012–2015, the overall proportion of isolates non-susceptible to penicillin or erythromycin increased by 3%, from 23% (n = 1, 183) to 26% (n = 1, 589; P < 0.05). However, a decrease of 3% would be expected if serotype redistribution occurred without within-serotype changes in non-susceptibility. Standardization by either factor produced hypothetical data significantly different to observed data. Within serotypes, the average annual increase in odds of non-susceptibility to penicillin or erythromycin was 1.08 (95% CI 1.05–1.11). Recent antibiotic exposure, urban residence and increased household size of participants predicted isolate non-susceptibility but did not explain the increase over time. Discussion: An overall increase in non-susceptibility of carried pneumococcal isolates to penicillin or erythromycin resulted from increases in non-susceptibility within serotypes, which outweighed a protective effect of serotype redistribution. Characterization of emerging resistant clones within carried non-vaccine serotypes, including risk factors for colonization and disease, would support disease prevention efforts and inform vaccine strategies.